Afimoxifene
Template:Chembox new
Afimoxifene[1] is a selective estrogen receptor modulator whose active ingredient is 4-hydroxytamoxifen which is identical to the active metabolite of tamoxifen.[2] Afimoxifene is a transdermal gel formulation and is being developed by Ascend Therapeutics, Inc. under the trademark TamoGel.[1] Afimoxifene has completed a phase II clinical trial for the treatment of cyclical mastalgia.[3]
References
- ↑ 1.0 1.1 "Statement on a nonproprietary name adopted by the USAN council: Afimoxifene" (PDF). American Medical Association. Retrieved 2008-03-26.
- ↑ Desta Z, Ward BA, Soukhova NV, Flockhart DA (2004). "Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6". J Pharmacol Exp Ther. 310 (3): 1062–75. doi:10.1124/jpet.104.065607. PMID 15159443.
- ↑ Mansel R, Goyal A, Nestour EL, Masini-Etévé V, O'Connell K (2007). "A phase II trial of Afimoxifene (4-hydroxytamoxifen gel) for cyclical mastalgia in premenopausal women". Breast Cancer Res. Treat. 106 (3): 389–97. doi:10.1007/s10549-007-9507-x. PMID 17351746.
External links
- 4-hydroxytamoxifen at the US National Library of Medicine Medical Subject Headings (MeSH)